论文信息 - A phase 1 study evaluating the safety and tolerability of otlertuzumab , an anti-CD 37 mono-speci fi c ADAPTIR therapeutic protein in chronic lymphocytic leukemia - 字舞流文

A phase 1 study evaluating the safety and tolerability of otlertuzumab , an anti-CD 37 mono-speci fi c ADAPTIR therapeutic protein in chronic lymphocytic leukemia

J. Byrd | J. Leonard | I. Flinn | F. Awan | J. Pagel | L. Andritsos | A. Forero | R. Furman | S. Stromatt | S. Spurgeon | A. Gopal | J. Bannink | A. Eisenfeld | D. Deauna-Limayo